© 1996 Oxford University Press
research-article |
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder
1Life Sciences Department, ITT Research Institute Chicago, IL 60616
2Chemoprevention Investigational Studies Branch, National Cancer Institute Bethesda, MD 20852, USA
3Present address: School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
4To whom correspondence should be addressed
In vivo studies were conducted to compare the activity of three non-steroidal anti-inflammatory drugs as inhibitors of urinary bladder carcinogenesis induced in B6D2F1 (BDF) mice by N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN). Mice received continuous dietary exposure to non-toxic doses of aspirin, sulindac or ketoprofen beginning 1 week prior to the first of eight weekly doses of 7.5 mg OH-BBN; studies were terminated at 24 weeks after the first carcinogen dose. Both dose levels of sulindac (200 and 400 mg/kg diet) and both dose levels of ketoprofen (40 and 80 mg/kg diet) reduced the incidence of transitional cell carcinoma of the urinary bladder by >70% from that seen in dietary controls. The high dose of sulindac conferred the greatest protection against bladder cancer induction. In contrast, when administered at 400 and 800 mg/kg diet aspirin was inactive as a chemopreventive agent in the OH-BBN/BDF bladder cancer model. The significant potency of sulindac and ketoprofen as inhibitors of urinary bladder carcinogenesis, when considered with their history of safe human use, suggests that these agents merit further study as drugs for cancer chemoprevention in this target tissue.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Fortuny, M. Kogevinas, M. Garcia-Closas, F. X. Real, A. Tardon, R. Garcia-Closas, C. Serra, A. Carrato, J. Lloreta, N. Rothman, et al. Use of Analgesics and Nonsteroidal Anti-inflammatory Drugs, Genetic Predisposition, and Bladder Cancer Risk in Spain. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1696 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Mohammed, D. Dhawan, S. Abraham, P. W. Snyder, D. J. Waters, B. A. Craig, M. Lu, L. Wu, R. Zheng, J. Stewart, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol. Cancer Ther., February 1, 2006; 5(2): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lubet, K. Huebner, L. Y.Y. Fong, D. C. Altieri, V. E. Steele, L. Kopelovich, C. Kavanaugh, M.M. Juliana, S.-j. Soong, and C. J. Grubbs 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin Carcinogenesis, March 1, 2005; 26(3): 571 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Sivak-Sears, J. A. Schwartzbaum, R. Miike, M. Moghadassi, and M. Wrensch Case-Control Study of Use of Nonsteroidal Antiinflammatory Drugs and Glioblastoma Multiforme Am. J. Epidemiol., June 15, 2004; 159(12): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin Carcinogenesis, May 1, 2004; 25(5): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Huguenin, F. Vacherot, L. Kheuang, J. Fleury-Feith, M.-C. Jaurand, M. Bolla, J.-P. Riffaud, and D. K. Chopin Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines Mol. Cancer Ther., March 1, 2004; 3(3): 291 - 298. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. J. Henry, D. L. McCaw, S. E. Turnquist, J. W. Tyler, L. Bravo, S. Sheafor, R. C. Straw, W. S. Dernell, B. R. Madewell, L. Jorgensen, et al. Clinical Evaluation of Mitoxantrone and Piroxicam in a Canine Model of Human Invasive Urinary Bladder Carcinoma Clin. Cancer Res., February 1, 2003; 9(2): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Grubbs, R. A. Lubet, A. T. Koki, K. M. Leahy, J. L. Masferrer, V. E. Steele, G. J. Kelloff, D. L. Hill, and K. Seibert Celecoxib Inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced Urinary Bladder Cancers in Male B6D2F1 Mice and Female Fischer-344 Rats Cancer Res., October 1, 2000; 60(20): 5599 - 5602. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Komhoff, Y. Guan, H. W. Shappell, L. Davis, G. Jack, Y. Shyr, M. O. Koch, S. B. Shappell, and M. D. Breyer Enhanced Expression of Cyclooxygenase-2 in High Grade Human Transitional Cell Bladder Carcinomas Am. J. Pathol., July 1, 2000; 157(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wolfle, S. Marotzki, D. Dartsch, W. Schafer, and H. Marquardt Induction of cyclooxygenase expression and enhancement of malignant cell transformation by 2,3,7,8-tetrachlorodibenzo- p-dioxin Carcinogenesis, January 1, 2000; 21(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans Am J Physiol Renal Physiol, December 1, 1997; 273(6): F1013 - F1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Reis, M. Roque, H. Dansky, J. T. Fallon, J. J. Badimon, C. Cordon-Cardo, S. J. Shiff, and E. A. Fisher Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice PNAS, November 7, 2000; 97(23): 12764 - 12769. [Abstract] [Full Text] [PDF]
|
|